
CMEF Autumn is an international trade platform covering the full medical device value chain, bringing together innovations in medical imaging, in vitro diagnostics, intelligent healthcare, rehabilitation, elderly care, and hospital infrastructure.
The 2025 autumn edition will take place in Guangzhou and leverage the industrial and trading strengths of the Greater Bay Area to connect manufacturers, distributors, hospital buyers, research institutions, and service providers across the healthcare market.
The event is also paired with conferences and themed programs focused on AI applications, digital transformation, regulatory compliance, niche-market innovation, and solutions for an aging population.




Reed Sinopharm Exhibitions is the exhibition and conference organizer in China's healthcare sector, established as a joint venture between Sinopharm (China's leading state-owned healthcare enterprise) and RX (a globally leading exhibition organizer). This strategic alliance combines deep industry insight with a global perspective.
With over 40 years of rooting in the Chinese pharmaceutical market, its flagship event API China serves as a vital gateway for global pharma companies to access China. Reed Sinopharm organizes dozens of professional exhibitions and conferences annually, covering the entire pharmaceutical value chain from R&D and manufacturing to distribution, and is widely recognized as the "barometer" of China's pharmaceutical industry.





Reed Sinopharm Exhibitions is the exhibition and conference organizer in China's healthcare sector, established as a joint venture between Sinopharm (China's leading state-owned healthcare enterprise) and RX (a globally leading exhibition organizer). This strategic alliance combines deep industry insight with a global perspective.
With over 40 years of rooting in the Chinese pharmaceutical market, its flagship event API China serves as a vital gateway for global pharma companies to access China. Reed Sinopharm organizes dozens of professional exhibitions and conferences annually, covering the entire pharmaceutical value chain from R&D and manufacturing to distribution, and is widely recognized as the "barometer" of China's pharmaceutical industry.